

GE Healthcare Life Sciences launches new Western Blotting system

25 September 2014 | News | By BioSpectrum Bureau

GE Healthcare Life Sciences launches New Western Blotting system



GE Healthcare Life Sciences has introduced Amersham WB system, a fully integrated system for quantitative SDS-PAGE and Western blotting of proteins using fluorescence detection. With this new system, every stage of the Western blotting process, including electrophoresis, transfer, probing and scanning, is standardised and monitored - resulting in consistent, quantitative protein analysis.

"Every life scientist has probably carried out a Western blot at some time in their career, and tens of thousands still do every week. The value of the insights provided by Western blotting has kept it relevant for more than 30 years, but its shortcomings are well-recognized. Building on GE's heritage and expertise in protein analysis, what we have developed is a system that is set to shift how scientists see and use Western blotting from now on, with a clear focus on reliability and quantification of results, regardless of user," said Mr Eric Roman, general manager of research and applied markets, GE Healthcare Life Sciences.

Mr Martin Teichert, research Scientist at DKFZ (German Cancer Research Center), Germany said, "The publication landscape has changed dramatically over the past year, and the need for quantified blots and data is of significant importance for peer-reviewed journals. I think that the Amersham WB system fits perfectly into this niche, and solves this problem of having quantifiable data that can be relied upon. It has arrived at just the right time."

GE Healthcare Life Sciences has developed this system, with a standardised traditional Western blotting workflow that typically achieves a variability of less than 10 per cent between users. The system's consistency and reproducibility delivers the robust quantitative data.